SAB Biotherapeutics, Inc. (SABS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -14.27M | -16.78M | -13.05M | -7.15M | -7.8M | -9.27M | -6.29M | -7.79M | -10.92M | -13.45M | -5.17M | -4.9M |
| Operating CF Margin % | - | - | - | - | - | -8083.04% | - | -2959.1% | -1155.8% | -4408.6% | -407.88% | -5728.8% |
| Operating CF Growth % | -83.03% | -80.95% | -107.41% | 8.15% | 28.58% | 31.05% | -21.75% | -58.94% | -579.91% | -6304.59% | 36.77% | -10.14% |
| Net Income | -18.87M | -16.86M | 5.34M | -10.11M | -5.2M | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M | -5.1M | -6.88M |
| Depreciation & Amortization | 752.67K | 763.3K | 765.47K | 774.52K | 778.3K | 785.71K | 966.86K | 1.02M | 1.98M | 944.4K | 985.45K | 892.27K |
| Stock-Based Compensation | 0 | 3.17M | 0 | 627.2K | 612.95K | 0 | 1.05M | 601.43K | 617.45K | 536.88K | 639.25K | 644.82K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.53M | 0 | 357.52K |
| Other Non-Cash Items | 5.91M | 3.47M | -20.78M | 618.21K | -5.06M | 3.22M | -54.53K | -2.34M | -5.72M | 10.89M | -195.47K | 50K |
| Working Capital Changes | -2.06M | -7.32M | 1.62M | 942.8K | 1.06M | -1.88M | 2.1M | 263.34K | -2.77M | -427.41K | -1.49M | 37.13K |
| Change in Receivables | -608.28K | -386.83K | -559.95K | 21.39K | 33.57K | 42.09K | 127.88K | 193.23K | -193.23K | 0 | 361.74K | 401.39K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -268.42K | -278.72K |
| Change in Payables | 114.12K | 324.53K | 335.92K | 138.17K | 684.17K | 590.38K | 134.62K | -45.04K | 243.36K | -105.77K | -320.68K | -41.11K |
| Cash from Investing | -65.65M | -1.71M | -129.87M | 5.2M | 4.67M | 9.33M | -1.15M | 11.22M | -31.36M | -67.86K | -40.86K | -22.68K |
| Capital Expenditures | -983.26K | -933.16K | 0 | 0 | 0 | -55.38K | -100.3K | -52.51K | -129.07K | -67.86K | -85.31K | -22.68K |
| CapEx % of Revenue | - | - | - | - | - | 48.28% | - | 19.96% | 13.66% | 22.25% | 6.73% | 26.53% |
| Acquisitions | 2.22K | 0 | 0 | 0 | 500 | 0 | 0 | 0 | 0 | 0 | 44.45K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 89.92M | -41.69K | 168.69M | -173.84K | -173.99K | -44.14K | -674.13K | -252.33K | -227.03K | 67.64M | -140.31K | -363.79K |
| Debt Issued (Net) | -37.39K | -168.77M | 168.69M | -173.84K | -171.91K | -19.21K | -649.13K | -252.33K | -247.44K | 477.76K | -142.74K | -363.79K |
| Equity Issued (Net) | 89.96M | 168.73M | 0 | 0 | 0 | -3 | 0 | 0 | 20.41K | 67.16M | 2.43K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -4.57K | -5.01K | -4.88K | 0 | -2.07K | -24.93K | -25K | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 10.02M | -18.92M | 25.73M | -1.95M | -3.26M | -273.21K | -8.07M | 3.21M | -42.53M | 54.14M | -5.35M | -5.29M |
| Free Cash Flow | -15.25M | -17.71M | -13.05M | -7.15M | -7.8M | -9.33M | -6.39M | -7.84M | -11.05M | -13.51M | -5.25M | -4.92M |
| FCF Margin % | - | - | - | - | - | -8131.32% | - | -2979.06% | -1169.47% | -4430.85% | -414.61% | -5755.33% |
| FCF Growth % | -95.64% | -89.89% | -104.15% | 8.77% | 29.41% | 30.99% | -21.69% | -59.27% | -578.94% | -13755.51% | 36.34% | 2.75% |
| FCF per Share | -0.28 | -0.29 | -0.17 | -0.77 | -0.84 | -1.01 | -0.69 | -0.85 | -1.20 | -2.28 | -1.00 | -0.98 |
| FCF Conversion (FCF/Net Income) | 0.76x | 0.99x | -0.29x | 0.71x | 1.50x | 0.81x | 0.61x | 1.06x | 2.17x | 0.59x | 1.01x | 0.71x |
| Interest Paid | 0 | 0 | 0 | 64.8K | 0 | 0 | 154.21K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |